Why the study?
Following WHO Emergency Use Listing of nOPV2 to control cVDPV outbreaks, extensive monitoring was required to assess the genetic stability of nOPV2 isolates during initial outbreak response.
Does nOPV2 maintain genetic stability during its initial use phase under Emergency Use Listing?
Does nOPV2 maintain genetic stability during its initial use phase under Emergency Use Listing?
Global genomic surveillance confirms the genetic stability of nOPV2, supporting its use as an important tool in the eradication of poliomyelitis.
No takes yet. Share an insight, caveat, or question.
Novel OPV2 shows early promise against cVDPV2; leaves open human efficacy and safety for outbreak control.
Martín et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: